Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib-melphalan-prednisolone vs lenalidomide-dexamethasone in transplant-ineligible newly diagnosed multiple myeloma
KCT0005006Phase 3Completed
- Sponsor
- Seoul St. Mary's Hospital
- Start
- Jun 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Bortezomib + melphalan + prednisolone with Lenalidomide + dexamethasone (2 arms). Started Jun 2020; status: completed.
02
Drugs
bortezomibmelphalanprednisolonelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on KCT0005006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005006.